Boxer Capital Management, LLC
Sector Allocation
- Healthcare99.7%$1.3B
- Other0.3%$4.5M
AUM History
13fpro.ai/research/fund/boxer-capital-management-llc-2018299
Conviction and streaks
Concentrating · top 10 = 65.1%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
TNGX
$340.0MRVMD
$93.6MABVX
$80.6MQURE
$69.2MKOD
$57.6MKYMR
$49.2MDFTX
$47.0MREPL
$44.1MCELC
$43.6MQTTB
$40.1MCAPR
$33.6MPGEN
$29.4MCORT
$29.2MSRZN
$27.0MPTGX
$20.8MVIR
$19.0MPCVX
$18.9MURGN
$18.4MCRVS
$16.4MPTCT
$16.3M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/boxer-capital-management-llc-2018299
Boxer Capital Management, LLC 13F holdings — Q2 2026
$1.3B portfolio (+74.3% QoQ) · 63 holdings · Q2 2026 13F · top 10 are 65% of the stock portfolio
$340.0M
25.6% of stocks
No changeThis quarter-13.3%Since filed7+ qtrsHeld$93.6M
7.0% of stocks
No changeThis quarter-9.7%Since filed7+ qtrsHeld$80.6M
6.1% of stocks
+203%This quarter-27.3%Since filed4 qtrsHeld$69.2M
5.2% of stocks
+127%This quarter-55.5%Since filed7+ qtrsHeld$57.6M
4.3% of stocks
+9%This quarter+116.7%Since filed7+ qtrsHeld$49.2M
3.7% of stocks
+30%This quarter-2.2%Since filed7+ qtrsHeld$47.0M
3.5% of stocks
+67%This quarter-16.3%Since filed2 qtrsHeldAIQualityAI quality score is Pro: unlock with a free trialEst. buyEstimated buy price is Pro: unlock with a free trialAdded 2 qtrs in a row$44.1M
3.3% of stocks
+239%This quarter-16.7%Since filed7+ qtrsHeldAIQualityAI quality score is Pro: unlock with a free trialEst. buyEstimated buy price is Pro: unlock with a free trialAdded 2 qtrs in a row$43.6M
3.3% of stocks
+85%This quarter-28.5%Since filed4 qtrsHeld$40.1M
3.0% of stocks
NewThis quarter-44.2%Since filedNew this quarterHeld
All holdings — Boxer Capital Management, LLC (Q2 2026)
63 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | CAPRICOR THERAPEUTICS, INC. | Healthcare | $33.6M | 2.5% | 1.40M | +136% | 3 qtrsAdded 3 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | PRECIGEN, INC. | Healthcare | $29.4M | 2.2% | 5.15M | +47% | 4 qtrsAdded 4 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | CORCEPT THERAPEUTICS INC | Healthcare | $29.2M | 2.2% | 336K | +34% | 2 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Surrozen, Inc./DE | Healthcare | $27.0M | 2.0% | 1.11M | +44% | 7+ qtrsAdded 3 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | Protagonist Therapeutics, Inc | Healthcare | $20.8M | 1.6% | 170K | — | 5 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | Vir Biotechnology, Inc. | Healthcare | $19.0M | 1.4% | 1.87M | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | Vaxcyte, Inc. | Healthcare | $18.9M | 1.4% | 325K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | UroGen Pharma Ltd. | Healthcare | $18.4M | 1.4% | 500K | — | 5 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | Corvus Pharmaceuticals, Inc. | Healthcare | $16.4M | 1.2% | 1.10M | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | PTC THERAPEUTICS, INC. | Healthcare | $16.3M | 1.2% | 200K | — | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | Praxis Precision Medicines, Inc. | Healthcare | $15.6M | 1.2% | 46K | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | Amylyx Pharmaceuticals, Inc. | Healthcare | $14.4M | 1.1% | 800K | — | 7+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | OCULAR THERAPEUTIX, INC | Healthcare | $12.8M | 1.0% | 1.30M | +271% | 2 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 24 | Opus Genetics, Inc. | Healthcare | $11.6M | 0.9% | 2.81M | +25% | 2 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 25 | PALISADE BIO, INC. | Healthcare | $10.0M | 0.8% | 4.80M | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 26 | $APGE | Apogee Therapeutics, Inc. | Healthcare | $9.3M | 0.7% | 70K | — | |||
| 27 | $SYRE | Spyre Therapeutics, Inc. | Healthcare | $8.9M | 0.7% | 100K | New | |||
| 28 | $COGT | Cogent Biosciences, Inc. | Healthcare | $8.7M | 0.7% | 225K | — | |||
| 29 | $CYTK | CYTOKINETICS INC | Healthcare | $8.5M | 0.6% | 100K | — | |||
| 30 | $RLAY | Relay Therapeutics, Inc. | Healthcare | $8.4M | 0.6% | 450K | New | |||
| 31 | $CBIO | CRESCENT BIOPHARMA, INC. | Healthcare | $8.2M | 0.6% | 454K | — | |||
| 32 | $CTNM | Contineum Therapeutics, Inc. | Healthcare | $8.1M | 0.6% | 494K | — | |||
| 33 | $KZIA | KAZIA THERAPEUTICS LTD | Healthcare | $7.9M | 0.6% | 560K | New | |||
| 34 | $STTK | Shattuck Labs, Inc. | Healthcare | $6.9M | 0.5% | 1.00M | New | |||
| 35 | $AVTX | Avalo Therapeutics, Inc. | Healthcare | $6.9M | 0.5% | 375K | +25% | |||
| 36 | $FBRX | Forte Biosciences, Inc. | Healthcare | $5.8M | 0.4% | 275K | New | |||
| 37 | $RLMD | RELMADA THERAPEUTICS, INC. | Healthcare | $5.8M | 0.4% | 842K | — | |||
| 38 | $MLTX | MoonLake Immunotherapeutics | Healthcare | $5.4M | 0.4% | 275K | — | |||
| 39 | $ZURA | Zura Bio Ltd | Healthcare | $5.3M | 0.4% | 900K | — | |||
| 40 | $HELP | Helus Pharma Inc. | Healthcare | $5.2M | 0.4% | 790K | +23% | |||
| 41 | $ODTX | Odyssey Therapeutics, Inc. | Healthcare | $5.1M | 0.4% | 275K | New | |||
| 42 | $IMTX | Immatics N.V. | Healthcare | $4.8M | 0.4% | 475K | New | |||
| 43 | — | FAETH THERAPEUTICS inc - COM NEW | — | $4.5M | 0.3% | 181K | New | |||
| 44 | $GPCR | Structure Therapeutics Inc. | Healthcare | $4.0M | 0.3% | 75K | — | |||
| 45 | $ORIC | Oric Pharmaceuticals, Inc. | Healthcare | $3.8M | 0.3% | 350K | +98% | |||
| 46 | $ANTX | AN2 Therapeutics, Inc. | Healthcare | $3.6M | 0.3% | 749K | — | |||
| 47 | $NMRA | Neumora Therapeutics, Inc. | Healthcare | $3.4M | 0.3% | 2.00M | New | |||
| 48 | $INO | INOVIO PHARMACEUTICALS, INC. | Healthcare | $3.1M | 0.2% | 2.84M | +20% | |||
| 49 | $ALLO | Allogene Therapeutics, Inc. | Healthcare | $3.1M | 0.2% | 1.50M | -45% | |||
| 50 | $SLDB | Solid Biosciences Inc. | Healthcare | $3.0M | 0.2% | 300K | — | |||
| 51 | $KPTI | Karyopharm Therapeutics Inc. | Healthcare | $3.0M | 0.2% | 303K | — | |||
| 52 | $CLNN | Clene Inc. | Healthcare | $2.9M | 0.2% | 478K | — | |||
| 53 | $SRPT | Sarepta Therapeutics, Inc. | Healthcare | $2.7M | 0.2% | 150K | — | |||
| 54 | $MPLT | MapLight Therapeutics, Inc. | Healthcare | $2.7M | 0.2% | 75K | New | |||
| 55 | $NRIX | Nurix Therapeutics, Inc. | Healthcare | $2.4M | 0.2% | 100K | — | |||
| 56 | $LBRX | LB PHARMACEUTICALS INC | Healthcare | $2.3M | 0.2% | 70K | — | |||
| 57 | $EDSA | Edesa Biotech, Inc. | Healthcare | $1.7M | 0.1% | 205K | New | |||
| 58 | $IVVD | Invivyd, Inc. | Healthcare | $1.3M | 0.1% | 1.50M | — | |||
| 59 | $UPB | Upstream Bio, Inc. | Healthcare | $1.0M | 0.1% | 150K | — | |||
| 60 | $MIST | Milestone Pharmaceuticals Inc. | Healthcare | $893K | 0.1% | 667K | — | |||
| 61 | $PEPG | PepGen Inc. | Healthcare | $491K | 0.0% | 273K | — | |||
| 62 | $RGNX | REGENXBIO Inc. | Healthcare | $180K | 0.0% | 15K | — | |||
| 63 | $SRZN | Surrozen, Inc./DE | Healthcare | $1K | 0.0% | 67K | — |
What changed in Q2 2026
Against the previous quarter's 13F: 12 new, 17 added to, 1 trimmed, 3 sold out. Share-count changes; largest moves by dollar size first.
New positions (12)
$QTTBQ32 Bio Inc.$40.1M
first bought this quarter
$SYRESpyre Therapeutics, Inc.$8.9M
first bought this quarter
$RLAYRelay Therapeutics, Inc.$8.4M
first bought this quarter
$KZIAKAZIA THERAPEUTICS LTD$7.9M
first bought this quarter
$STTKShattuck Labs, Inc.$6.9M
first bought this quarter
$FBRXForte Biosciences, Inc.$5.8M
first bought this quarter
+6 more in the Excel export
Added to (17)
$ABVXAbivax S.A.+203%
now $80.6M · held 4 qtrs, 4 adds in a row
$QUREuniQure N.V.+127%
now $69.2M · held 7+ qtrs, 2 adds in a row
$REPLReplimune Group, Inc.+239%
now $44.1M · held 7+ qtrs, 2 adds in a row
$CELCCelcuity Inc.+85%
now $43.6M · held 4 qtrs
$CAPRCAPRICOR THERAPEUTICS, INC.+136%
now $33.6M · held 3 qtrs, 3 adds in a row
$DFTXDefinium Therapeutics, Inc.+67%
now $47.0M · held 2 qtrs, 2 adds in a row
+11 more in the Excel export
Trimmed (1)
$ALLOAllogene Therapeutics, Inc.-45%
now $3.1M · held 2 qtrs
Holdings by quarter
Every 13F Boxer Capital Management, LLC has filed, 6 earlier quarters. Pick one to see what it held then.
Is it too late to follow Boxer Capital Management?
Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of Boxer Capital Management's top 20 holdings: 26/100 (our AI quality score, weighted by position size; 9 of the 20 are scored)
Top 10 since filing
-10.8%
Value-weighted move of the 10 largest stock positions
Turnover
3%
Last quarter; 50% over the last 4
Top 10 weight
65%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
72%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
Boxer Capital Management, LLC disclosed 63 positions worth $1.3B in its Form 13F-HR for Q2 2026, led by $TNGX (Tango Therapeutics, Inc.) at 25.6% of the equity portfolio, followed by $RVMD and $ABVX. During the quarter the fund opened 12 new positions and exited 3 — including a new stake in $QTTB and a full exit from $TERN. The portfolio is most concentrated in Healthcare (99.7% of disclosed assets). All figures are sourced directly from Boxer Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 2018299.
Funds like this
managers whose biggest positions overlap Boxer Capital Management'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: Boxer Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Boxer Capital Management, LLC (SEC CIK: 2018299), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Boxer Capital Management, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.